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Abstract: Autism spectrum disorders (ASD) are a group of neurodevelopmental disorders
characterized by deficits in social interaction and communication, and repetitive behaviors. In addition,
co-morbidities such as gastro-intestinal problems have frequently been reported. Mutations and
deletion of proteins of the SH3 and multiple ankyrin repeat domains (SHANK) gene-family were
identified in patients with ASD, and Shank knock-out mouse models display autism-like phenotypes.
SHANK3 proteins are not only expressed in the central nervous system (CNS). Here, we show
expression in gastrointestinal (GI) epithelium and report a significantly different GI morphology in
Shank3 knock-out (KO) mice. Further, we detected a significantly altered microbiota composition
measured in feces of Shank3 KO mice that may contribute to inflammatory responses affecting brain
development. In line with this, we found higher E. coli lipopolysaccharide levels in liver samples of
Shank3 KO mice, and detected an increase in Interleukin-6 and activated astrocytes in Shank3 KO
mice. We conclude that apart from its well-known role in the CNS, SHANK3 plays a specific role in
the GI tract that may contribute to the ASD phenotype by extracerebral mechanisms.
Keywords: microbiome; gut; ProSAP2; Phelan McDermid Syndrome; gut–brain interaction; leaky
gut; IL-6; SHANK
1. Introduction
SHANK3 (SH3 and multiple ankyrin repeat domains 3, also known as proline-rich
synapse-associated protein 2 (ProSAP2)) is a known scaffolding protein of the postsynaptic density
(PSD) of glutamatergic excitatory synapses [1–3] that has been associated with autism spectrum
disorders (ASD) [4–7]. Further, the Phelan McDermid Syndrome (PMDS/22q13.3 deletion syndrome) is
a rare genetic disorder associated with a heterozygous loss of SHANK3 in the majority of patients.
Individuals with PMDS show symptoms of the autism spectrum along with mental retardation and
muscular hypotonia, and can suffer from seizures and gastrointestinal (GI) problems [8–10]. Besides
the CNS, SHANK3 is expressed in different levels in many tissues, such as liver, heart, kidney, skeletal
muscle [8], and epithelial cells of the GI tract [11,12].
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A growing number of studies indicate a role of abnormal development and function of the
gastro-intestinal (GI) system as a factor in ASD, with many patients having symptoms associated with
GI disorders [13]. Research indicates a link between the dysfunctions associated with ASD and GI
problems such as abnormal trace metal uptake, alterations in the microbiome, and immune dysfunction
and inflammatory processes [13,14]. In line with this, we have reported expression of SHANK3 in
human enterocytes, where SHANK3 was functionally linked to zinc (Zn) transporter levels mediating
Zn absorption [12].
The gut harbors a complex community of microbes—the microbiome—that is able to influence,
among others, the development of the central nervous system (CNS) [15]. Recently, a study identified
a dysregulation of several genera and species of bacteria in the gut and colon of Shank3 KO mice [16]
and the treatment of Shank3 KO mice with L. reuteri led to the attenuation of some ASD-associated
behaviors [16]. However, the underlying factors of the altered microbiota composition are currently
not well understood.
Thus, here, we made use of a Shank3αβ knock-out mouse line that was reported to display
ASD-like behavior with abnormal ultrasonic vocalization, repetitive self-grooming, and reduced
interest in novel mice in nonsocial versus novel social pairing in the three-chamber test [17,18]. In these
animals we performed a detailed analysis of the GI tract including further analyses determining
microbiota composition. Our results confirm expression of SHANK3 in the GI epithelium. Further,
Shank3αβ knock-out mice display an altered GI morphology and, in line with published data [16]
we can confirm changes in gut microbiota composition. Altered GI morphology and microbiota
composition lead to exaggerated responses to bacterial metabolites and compounds eliciting an
immune response [19]. An increase of inflammatory markers has been reported in individuals with
ASD and animal models [20,21]. Especially the cytokine Interleukin-6 (IL-6) has been proposed as a
biomarker for autism [22] and was shown to be mechanistically linked to the development of autistic
behaviors in mice [23–25]. Intriguingly, we detected an increase in IL-6 levels in Shank3αβ knock-out
mice along with increased activation of astrocytes in the frontal cortex of Shank3αβ knock-out mice.
Astrocyte activation has previously been linked to ASD [26].
2. Results
2.1. SHANK3 is Expressed in GI Epithelium of Mice
In the first set of experiments, we investigated the GI system of Shank3αβ KO mice that have been
characterized in the lab previously [27]. Using the method described by Nik and Carlsson [28], we
separated intestinal epithelium from mesenchyme. The purity of the lysate was confirmed by Western
Blot analysis of the expression of Vimentin, whose presence would indicate unsuccessful separation of
the epithelium, and Cytokeratin 7, which should be found in epithelium but not in mesenchymal cells
of the submucosa (Figure S1). Apart from the expression of many ASD-associated genes [29] normally
found at synapses in the CNS, we detected mRNA of SHANK family proteins and their “synaptic”
interaction partners in GI epithelium (Figure 1A).
On protein level, in wildtype animals, only expression of SHANK2 and SHANK3, but not SHANK1
was found in GI epithelium in mice (Figure 1B). Further, in gut epithelium obtained from Shank3αβ
KO mice, gene expression of Shank2 and Shank3 was decreased in comparison to wild type controls
(Figure 1C). Knock-out animals do not show a total loss of Shank3 due to the expression of the Shank3γ
isoform that is detected by qRT-PCR primers.
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Figure 1. Expression of autism spectrum disorder (ASD)-associated postsynaptic density (PSD) proteins
in gut epithelial cells. Several further ASD-associated PSD proteins are expressed in gut epithelial
cells. (A) Screening of lysate from wild type mice (n = 5; used in technical triplicates) from isolated
gut epithelium for the expression of “synaptic” ASD-associated genes using qRT-PCR. The genes
were selected based on their occurrence at excitatory postsynapses and a reported association with
ASD. On mRNA level, expression of all SH3 and multiple ankyrin repeat domains (Shank) family
members was detected, as well as the expression of several direct interacting proteins such as Abi1
(Abelson interactor 1), and Homer1 (Homer protein homolog 1). Furthermore, the expression of
Apc (Adenomatous-polyposis-coli), Arhgef6 (Rac/Cdc42 Guanine Nucleotide Exchange Factor (GEF)
6, Alpha-PIX), Cask (Calcium/Calmodulin-Dependent Serine Protein Kinase), Cntnap1 (Contactin
Associated Protein 1), Crkl (V-Crk Avian Sarcoma Virus CT10 Oncogene Homolog-Like), Cyfip1
(Cytoplasmic FMR1 Interacting Protein 1), Disc1 (Disrupted In Schizophrenia 1), Dlg1 (Discs, Large
Homolog 1), Doc2a (Double C2-Like Domains, Alpha), Fkbp1a (FK506 Binding Protein 1A), Fmr1 (Fragile
X Mental Retardation 1), Gdi1 (GDP Dissociation Inhibitor 1), Il1apl1, Limk1 (LIM Domain Kinase 1),
Mapk1 and Mapk3 (Mitogen-Activated Protein Kinase 1 and 3), Nf1 (Neurofibromin 1), and Syngap1
(Synaptic Ras GTPase Activating Protein 1) was detected. (B) Western Blot analysis for the expression
of SHANK family members SHANK1, SHANK2, and SHANK3 using GI epithelium and brain tissue
from wild-type mice. Only expression of SHANK2 and SHANK3 was detected on protein level in GI
epithelium (full arrows). (C) Expression-analysis Shank2 and Shank3 in wildtype and Shank3αβ KO
mice. Significantly lower expression of Shank2 was found in Shank3αβ KO mice (t-test, 3 technical
replicates from 3 animals per group; Shank2 p = 0.0067 (n = 3); ** p < 0.01).
2.2. Shank3 KO Mice Show Abnormal GI Morphology
Shank3αβ KO mice did not show signs of diarrhea, stool blood, weight loss, or increased
mortality. However, the analysis of the GI tract of Shank3αβ KO mice revealed significantly altered
gut morphology (Figure 2A–D). Using paraffin-embedded sections from intestine, we performed
histological and morphometric analyses. Shank3αβ KO mice show a significantly decreased length, but
not width, of small intestinal villi compared to wild type mice (Figure 2B,C). Given that the crypt depth
remains unchanged in Shank3αβ KO mice (Figure 2D), the ratio between villi length and crypt depth,
which is considered normal in a range between 3 and 5, is reduced to below 3 in Shank3αβ KO mice.
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Figure 2. Altered gut morphology in Shank3αβ knock-out (KO) mice. (A–D) Histological evaluation 
of GI tract from wild type and Shank3αβ KO mice. (A) Longitudinal cross sections of Shank3αβ KO 
mice and wild type (WT) mice were stained with hematoxylin/eosin (HE) (upper panels) and periodic 
acid schiff (PAS) reaction (lower panels). Exemplary images are shown. (B–D) Morphological analysis 
of (B) villi length and (C) width, and (D) crypt depth reveals a significantly decreased villi length 
Figure 2. Altered gut morphology in Shank3αβ knock-out (KO) mice. (A–D) Histological evaluation
of GI tract from wild type and Shank3αβ KO mice. (A) Longitudinal cross sections of Shank3αβ KO
mice and wild type (WT) mice were stained with hematoxylin/eosin (HE) (upper panels) and periodic
acid schiff (PAS) reaction (lower panels). Exemplary images are shown. (B–D) Morphological analysis
of (B) villi length and (C) width, and (D) crypt depth reveals a significantly decreased villi length
(Mann-Whitney U-test, p = 0.009; n = 5 animals per group) but not width (p = 0.534), and normal
crypt depth (p = 0.983) in Shank3αβ KO mice. (E,F) Immunohistochemistry was performed on 5 mice
per group and 5 optic fields of view each from 3 sections per mouse were analyzed. (E) A slight but
non-significant decrease in FABP2 signal intensity was observed in Shank3αβ KO mice compared to
wild types (left panel). Significantly higher ZONULIN-1 levels were found in Shank3αβ KO mice
(right panel) (t-test, p = 0.0413). (F) The levels of CLAUDIN3 and lipopolysaccharide (LPS) were not
significantly different between Shank3αβ KO mice and wild types in gut epithelium. (G) Significantly
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higher ZONULIN-1 levels in Shank3αβ KO mice were confirmed by western blotting using gut
epithelium protein lysate (t-test, p = 0.0434, n = 3 per group). (H) Protein lysate from liver tissue from
WT and Shank3αβ KO mice (n = 3 per group) were analyzed for E. coli LPS levels using Western Blotting.
The results show significantly higher LPS levels in the liver of Shank3αβ β KO mice (t-test, p = 0.0452).
* p < 0.05, ** p < 0.01.
Further analyses of the GI epithelium using immunohistochemistry and protein biochemistry
revealed further alterations. We selected three markers, FABP2 (Intestinal fatty acid-binding protein 2),
CLAUDIN3, and ZONULIN1 (Figure 2E,F). FABP2 is a cytosolic protein found in small intestine
epithelial cells where it participates in the uptake, intracellular metabolism, and transport of long chain
fatty acids. CLAUDIN3 is a cell adhesion protein found at tight junctions between gut epithelial cells.
ZONULIN1 is a modulator of tight junctions and alterations in the ZONULIN-regulated pathways
have been associated with both intestinal and extra-intestinal inflammatory disorders [30]. Especially a
decrease in FABP2 and increase in ZONULIN1 have been proposed as markers of gut dysbiosis and gut
permeability integrity [31]. Protein levels were assessed measuring fluorescence intensities. The results
reveal slight but not significantly lower levels of FABP2 in Shank3αβ KO mice. In contrast, the levels of
ZONULIN1 were significantly higher in Shank3αβ KO mice compared to wild types (Figure 2E). This
result was confirmed using gut epithelial protein lysate and western blotting (Figure 2G). No significant
differences were found in CLAUDIN3 levels (Figure 2F).
A loss of intestinal barrier function was reported secondary to upregulation of ZONULIN, which
is, to our knowledge, the only known physiological modulator of intercellular tight junctions [32].
Increased intestinal permeability may be responsible for increased translocation of bacterial components
and metabolites into the systemic circulation [33]. Given the observed abnormalities in GI epithelium,
we therefore investigated next whether the abnormal GI morphology of Shank3αβ KO mice facilitates
the enrichment of bacterial compounds in the host system.
Lipopolysaccharide (LPS) levels from bacterial origin were not significantly different in the GI
epithelium between Shank3αβ KO and wild type mice (Figure 2F). Detoxification and degradation of
microbial products from gut-derived microbiota is a function of the liver. In the liver, hepatocytes
mediate the clearance of endotoxin of intestinal origin [34]. Interestingly, when we analyzed liver
samples regarding the levels of bacterial (E. coli) LPS, we found a significant increase in liver LPS in
Shank3αβ KO mice (Figure 2G), hinting at increased LPS absorption (leakiness) of the GI system.
2.3. The Microbiome of Shank3 KO Mice Is Altered
Abnormalities in the GI system might translate into persistent changes that may affect several
processes and features such as microbiota composition and may cause chronic inflammatory activity.
Altered composition of gut microbiota has been reported before in Shank3 KO mice [16]. Thus, in the
next set of experiments, we assessed the microbiome of Shank3αβ KO mice to confirm the presence
of alterations in our mice. Feces from 10 weeks old Shank3αβ KO mice were collected and compared
to age and gender matched controls. Housing conditions of the mice (bedding material, nesting
material, number of animals per cage) were the same between groups and animals were housed side
by side in wire cages. DNA was extracted from feces from four mice and pooled to one sample and
three samples per group were analyzed using 16s microbiome profiling (Figure 3). The results show
significant alterations in the microbiome of Shankαβ KO mice compared to Controls (Figure S2A,B).
The amount of Actinobacteria was significantly higher in feces from Shank3αβ KO mice (Figure 3A).
While the amount of Bacterioidetes (Figure 3B) was not altered, significantly higher levels of Firmicutes
(Figure 3C) were detected in Shank3αβ KO mice. Further, only in Shank3αβ KO mice, Deferribacteres
(Figure 3D), Tenericutes (Figure 3F), and Chlamydiae (Figure 3H) were found. In contrast, significantly
lower levels of Proteobacteria (Figure 3E) and Verrucomicrobia (Figure 3G) were detected. In general,
the phyla Firmicutes and Proteobacteria dominate the microbiome of control mice, while a shift towards
Firmicutes and Actinobacteria occurs in Shank3αβ KO mice (Figure 3I).
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different animals were pooled per sample and three samples per group were analyzed. (A) The 
amount of Actinobacteria is significantly higher in feces from Shank3αβ KO mice. (B) The amount of 
Bacterioidetes is not significantly different between control and Shank3αβ KO mice. (C) A significant 
increase in Firmicutes was found in Shank3αβ KO mice. (D) Bacteria of the phylum Deferribacteres 
Figure 3. Altered microbiome in Shank3αβ KO mice. DNA was extracted from feces from 10 weeks
old animals and microbiome analysis was performed using 16S Microbiome Profiling. Feces from
four differ t i als ere p oled per sample and three samples per group were analyzed. (A) The
amount f Actinobacteria is significantly highe s from Shank3αβ KO mice. (B) The am unt of
Bacterioidetes is not significantly differ nt betwe trol and Shank3αβ KO mice. (C) A sig ificant
increase in Firmicutes was found in Shank3αβ KO mice. (D) Bacteria of the phylum Deferribacteres were
only found in Shank3αβ KO mice. (E) Significantly reduced levels of Proteobacteria were detected
in Shank3αβ KO mice. (F) Bacteria of the phylum Tenericutes were only found in Shank3αβ KO mice.
(G) The amount of Verrucomicrobia was significantly lower in Shank3αβ KO mice. (H) Bacteria of the
phylum Chlamydiae were only found in Shank3αβ KO mice. (I) Overview of the identified relative
frequencies of different phyla found in control and Shank3αβ KO mice. (J) The increase in Actinobacteria
is caused by a significant increase in both classes Actinobacteria (order Bifidobacteriales) (t-test, p < 0.0001)
and Coriobacteria (t-test, p < 0.0001). (K) Coriobacteria increase due to a significant higher levels in the
order Eggerthellales, but not Coriobacteriales. (L) Within the family Eggerthellaceae, Adlercreutzia did
not show an increase. The genera Asaccharobacter, Eggerthella, Enterorhabdus, and Paraeggerthella show
significant increase. * p < 0.05, *** p < 0.001.
Given that an increase in Actinobacteria in the gut of Shank3 KO mice has been reported before [16],
we closer investigated the alterations within this phylum. The increase in Actinobacteria was caused by a
significant increase in the order Bifidobacteriales (class Actinobacteria) and Eggerthellales (class Coriobacteria)
(Figure 3J,K). Both orders consist of one detected family, Bifidobacteriaceae and Eggerthellaceae, respectively.
Within the family Bifidobacteriaceae, only bacteria of the genus Bifidobacterium were detected. Within
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the family Eggerthellaceae, the genus Adlercreutzia did not show an increase, while bacteria of the genus
Asaccharobacter, Eggerthella, Enterorhabdus, and Paraeggerthella increased in abundance (Figure 3L).
In particular, the bacteria species Bifidobacterium pseudolongum, Assacharobacter WCA-131-CoC-2,
Eggerthella YY7918, and Enterorhabdus caecimuris were drivers of this increase (Figure S2C), which
have been associated with inflammation and infection of the gastrointestinal tract [35,36]. However,
classification on species level using 16S RNA sequencing cannot be done with a high level of confidence
and needs to be confirmed by more detailed studies in the future. Another limitation of the performed
analysis is that mice have been pooled into three samples, which obscures inter-individual differences.
For analysis, we assumed a normal distribution of data. While pooled samples within one group
showed great homogeneity, high levels of variability on individual level are not uncommon for
microbiota composition.
2.4. Altered GI Morphology and Microbiome of Shank3 KO Mice May Be Linked to Increased Inflammatory
Marker Expression
One hypothesis that has been proposed for ASD is that GI pathologies such as a “leaky gut” will
expose the host to epitopes from microbiota that reside within the gut in altered composition, and
thereby produce an immune activation leading to inflammatory responses, which may contribute to
CNS pathologies during certain time-windows in development. Altered inflammatory cytokine levels
have been reported recently in Shank3 KO mice [16].
Therefore, next, to investigate whether higher intestinal barrier dysfunction of Shank3αβ KO mice
might translate into increased expression of inflammatory markers, we analyzed the expression of
Glial fibrillary acidic protein (GFAP), a marker for astrogliosis, in the cortex of WT and Shank3αβ
KO mice using immunohistochemistry. Our results reveal a significantly increased number of GFAP
positive cells in Shank3αβ KO mice (Figure 4A). Further, because of its importance in relation to
ASD, we analyzed IL-6 levels in brain sections of Shank3αβ KO mice. IL-6 signals resulted from
diffuse staining of neural tissue and signals from blood vessels. The immunofluorescence of IL-6 was
slightly, but not significantly, higher in neural tissue of Shank3αβ KO mice compared to WT (Figure 4B).
In contrast, signals in blood vessels were significantly increased in Shank3αβ KO mice (Figure 4B)
hinting at a systemic increase of IL-6 as previously reported in individuals with ASD.
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Figure 4. Confocal microscopy images with same acquisition time taken from frontal cortex of brain
sections from WT and Shank3αβ KO mice (n = 3 animals per group) were used to assess the number of
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activated astrocytes labeled by Glial fibrillary acidic protein (GFAP), and IL-6 levels in neural tissue
and blood vessels. DAPI staining was used to visualize cell nuclei. (A) Optic fields (OF) of view were
analyzed and the number of GFAP positive cells per OF measured. The results show a significantly higher
number of activated astrocytes in Shank3αβ KO mice (t-test, p = 0.0407). (B) The immunofluorescence
of IL-6 was slightly higher in Shank3αβ KO mice compared to WT (t-test, p = 0.1164) in neural tissue
and significantly higher in blood vessels (t-test, p = 0.0014). * p < 0.05, ** p < 0.01.
3. Discussion
A growing amount of research reveals abnormalities in the GI system of ASD patients with
many of them having symptoms associated with GI disorders. It is likely that these extracerebral
alterations contribute to and modify the pathology of ASD. Here, we investigated Shank3αβ KO mice
and found significant GI abnormalities that translated into altered microbiota composition, increased
accumulation of bacterial LPS in liver, and signs of increased immune activation in the periphery and
the brain.
The structural and functional integrity of the gastrointestinal mucosal barrier is important
for protection from various luminal agents such as acids, enzymes, bacteria, viruses, and toxins.
The abnormal GI morphology may lead to downstream effects resulting in the often-reported GI-related
symptoms and co-morbidities in ASD [13]. One frequently reported GI alteration in ASD is an
altered microbiome. In mammals, intestinal microbiota have a marked influence on health status via
gut–brain–microbiota interactions [37,38]. In humans, stool was shown to contain a high bacterial
composition, with >90% of sequence data belonging to bacteria [39], with predominately bacteria
belonging to two phyla, Firmicutes and Bacteriodetes [39]. Interestingly, feces of mice also showed mostly
bacteria from the phyla Firmicutes and Bacteriodetes in our analyses. The dysbiosis we observed in
Shank3αβ KO mice is marked by an increase in microbiota of the phylum Actinobacteria and Firmicutes,
and bacteria from the phylum Tenericutes, Deferribacteres, and Chlamydiae were only present in Shank3αβ
KO mice, while the mount of Proteobacteria and Verrucomicrobia was lower. Interestingly, in humans,
a significant increase in the Actinobacterium phylum was found in patients with ASD [40]. Our results
are also in line with the previous reported alterations in gut microbiota of Shank3 KO mice [16], where
similar to our results, an increase in Actinobacteria was reported. The consistent increase in Actinobacteria
in two distinct Shank3 KO models housed in different animal facilities therefore arises as consistent
pattern with relation to ASD in humans.
On genus level, we found a significant increase in Enterorhabdus and Mucispirillum in Shank3αβ
KO mice. Both genera contain species that have been associated with both inflammatory markers
and active colitis [36,41]. In particular, Mucispirillum expansion has been observed during intestinal
inflammation [41]. In addition, we observed an increase in the Clostridium genus. Bacteria of this genus
are major producers of toxins and an increase has been reported in ASD [40,42]. Further, Shank3αβ KO
mice show significantly higher levels of Parasutterella. Parasutterella were reported to be characteristic
for patients with Crohn’s disease [43] but they also emerged as significantly associated with children
with Autism and functional gastrointestinal disorders that experience abdominal pain [44]. Among the
genera significantly decreased in Shank3αβ KO mice were Akkermansia. Akkermansia (e.g., Akkermansi
muciniphila) were found low in feces of children with autism [45]. In general, a picture emerges where
the observed alterations in the microbiota composition of Shank3αβ KO mice support a model of
increased inflammation.
In ASD, dysbiosis of microbiota has been associated with a disruption of the mucosal barrier
leading to alteration in the intestinal permeability [46], which may cause a change in the inflammatory
status of mice, a major process in the interaction between gut and brain. In our study, we could confirm
the previously reported expression of Shank3 in gut epithelial cells [12]. Loss of Shank3αβ in mice not
only produces a phenotype in nervous tissue. Here, we report abnormal GI morphology. The length of
villi was reduced in Shank3αβ KO mice and ZONULIN expressed at significantly higher level.
Int. J. Mol. Sci. 2019, 20, 2134 9 of 15
Increased intestinal permeability has been recently proposed to play a key role in the pathogenesis
of chronic inflammatory diseases [32], such as irritable bowel syndrome [47], but also ASD [48]. Since
the intestinal epithelium provides the interface between host and environment, inappropriate antigen
trafficking through the intestinal mucosa may occur upon increased intestinal permeability. While
under normal physiological conditions, the majority of antigens passes through the transcellular
pathway, where lysosomal degradation produces small non-immunogenic peptides, only ∼10% of
proteins cross the epithelium through the paracellular pathway as full intact proteins or partially
digested peptides. This results in antigenic tolerance, which can be severely affected in case this
ratio changes [32]. Intestinal permeability in turn is tightly connected to microbiota composition.
ZONULIN is a major regulator of intestinal permeability and an increase in ZONULIN as observed
here in Shank3αβ KO mice has been associated with increased permeability [49].
In line with this, we could show that bacterial LPS accumulates in significantly higher amount in
the liver of Shank3αβ KO mice. Together, these results hint towards a disruption of the mucosal barrier.
We could further confirm the increased expression of inflammatory markers in Shank3 KO mice.
In particular, we observed significantly higher IL-6 levels in the capillary network within the brain
of Shank3αβ KO mice, likely reflecting higher systemic IL-6 levels. Increased serum cytokine levels
in autistic patients have previously been modeled in mice by maternal immune activation (MIA).
MIA results in the production of inflammatory cytokines leading to neurological and immunological
disturbances in the offspring resulting in autism-like behavioral deficits. These studies have pointed
towards IL-6 as a key cytokine involved in these events [25]. During inflammation, IL-6 was shown to
induce the expression of other cytokines and immune regulatory genes. In addition, IL-6 can initiate
the transcription of neural regulatory genes [25]. Intriguingly, administration of an anti-IL-6 antibody
in MIA mice rescued some of the behavioral deficits.
The increased levels of IL-6 were accompanied by significantly increased number of GFAP positive
cells in the brain of Shank3αβ KO mice. GFAP expression is a marker for astrogliosis [50] and increased
levels of GFAP expression in cortex were also reported in some human individuals with ASD [51].
Taken together, in line with our previous report on SHANK3 in the GI tract [12] the presence of
other “synaptic” proteins in the GI epithelium makes the existence of a protein complex similar to the
one described at excitatory postsynapses in enterocytes more than likely. The loss of this complex may
lead to morphological and functional abnormalities in the GI tract, ultimately resulting in alterations
in the microbiome and the passage of bacterial metabolites and compounds into the host animal.
While our data shows correlation and not causation, these molecules may act as trigger for immune
responses leading to increased levels of cytokines, among them IL-6 causing an inflammatory response
that ultimately will affect brain development and function, e.g., via the activation of astrocytes. Thus,
the contribution of extracerebral factors to the phenotype of SHANK3 deficient mice and humans is
likely. The possibility of specific interventions to alter the microbiome may provide new vistas for
novel therapeutic approaches such as dietary manipulations in ASD.
4. Materials and Methods
4.1. Materials
Paraformaldehyde was purchased from Merck and D-Saccharose was from Roth, Karlsruhe,
Germany. Alexa Fluor conjugated secondary antibodies and ProLong® Gold antifade reagent from
Invitrogen/Life Technologies Europe, Darmstadt, Germany. Zonulin 1 antibody was purchased from
Thermo Fisher Scientific (Invitrogen) (Waltham, MA, USA); Claudin3 antibody from Abcam (Berlin,
Germany); FABP2 antibody from Thermo Fisher Scientific (Invitrogen); LPS antibody from Origene
(Rockville, MD, USA); and IL6 antibody was purchased from Cell signaling Technologies (Danvers,
MA, USA); GFAP antibody was purchased from Sigma Aldrich (St. Louis, MO, USA); Cytokeratin and
Vimentin antibody from Abcam. For SHANK3 western blotting in-house polyclonal rabbit SHANK3
antibodies were used that have been described previously [27,52]. iScriptTM cDNA Synthesis Kit,
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SSoAdvanced Universal SYBR® Green Supermix and customized PrimePCR plates were purchased
from Bio-Rad, Hercules, CA, USA. QuantiTect Primer Assays, RNeasy Mini Kit and QuantiFastTM
SYBR_Green RT-PCR kit were purchased from Qiagen, Hilden, Germany. Unless otherwise indicated,
all other chemicals were obtained from Sigma-Aldrich.
4.2. Animals
Shank3αβ mutants were published and characterized before and raised on a C57BL/6
background [27]. All animal experiments were performed in compliance with the guidelines for the
welfare of experimental animals issued by the Federal Government of Germany and approved by the
Regierungspraesidium Tuebingen and the local ethics committee (Ulm University) (project code - O.103,
date of approval May 12th 2016). Both wild type and Shank3αβ KO mice received the same standard
laboratory diet (ssniff GmbH, Germany) and consumed similar amounts of food and water that was
accessed ad libitum.
4.3. Microbiome Analysis
DNA extraction—DNA extraction of murine fecal samples was performed using the Mo Bio
PowerFecal DNA Isolation Kit (Qiagen, Hilden, Germany) according to the manufacturer´s protocol.
After elution, the resulting DNA concentration was measured on the Nanodrop 2000 (Thermo Fisher
Scientific, Waltham, MA, USA). Purity was assessed by calculating the measured A260/A280 ratio
using a Nanodrop. DNA samples with an A260/A280 ratio in between 1.7 to 2.0 were considered pure
and used for MiSeq.
Pyrosequencing of 16S rDNA region V3 to V5—Primers were designed to target conserved
sequences around the variable region 3 to 5 (V3 to V5) of bacterial 16S rDNA. 16s Microbiome Profiling
with MiSeq was performed by Eurofins Genomics (Ebersberg, Germany).
Pyrosequencing data processing and taxonomic classification—Data processing and taxonomic
classification was performed by Eurofins Genomics. In brief, after removing all reads with errors, the
remaining reads were processed using minimum entropy decomposition (MED), thereby partitioning
the marker gene dataset into OTUs (Operational Taxonomic Units). Taxonomic information was
assigned to each OTU by BLAST alignments of representative cluster sequences to the NCBI database.
A specific taxonomic assignment for each OUT was transferred from a set of best-matching reference
sequences. Only reference sequences with an 80% sequence identity across at least 80% of the
sequence were considered for reference purposes. Sequences were not assigned to an OTU if they were
considered as noise according to the OTU picking algorithm (including potential chimeric sequences
and singletons). OTU and taxonomic assignments were further processed with the QIIME software
package (version 1.8.0, http://qiime.org/). Normalization after Angly [53] of bacterial and archaea
taxonomic assignment abundance with lineage specific copy numbers of marker genes was performed
for estimate improvement. Therefore, the number of reads assigned to one species was divided by a
known or assumed number of marker regions/genes.
Statistical analysis was performed testing for significance without correction for multiple
comparisons due to the low number of simultaneous tested hypotheses. Correction for multiple
comparisons does not alter results reported in the manuscript with the exception of differences observed
for Proteobacteria on phylum level.
4.4. Immunohistochemistry
Paraffin-embedded sections of small intestine were cut at 4.5 to 5 µm thickness. Afterwards,
sections were treated with Xylene 2× for 5 min each and submerged in 100%, 90%, 70% Ethanol and H2O
for 5 min each. Sections were treated in 10 mM sodium citrat buffer pH 6.0 for 15 min around boiling
point (Microwave at 600 W). The slides were cooled down to room temperature (RT) for approximately
30 min und washed two times in PBS for 2 min each. The tissue on each slide was surrounded with a
fat tissue stick. To avoid unspecific antibody binding the tissue was blocked with blocking solution
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(BS) (10% FBS in 1× PBS) for 1 h at RT. Subsequently, the tissue was incubated with primary antibody
diluted in BS for 2 h at RT in a humid chamber. After washing 3×with PBS for 5 min, the tissue was
incubated with secondary antibody, diluted in BS, for 1 h in a humid chamber, followed by a wash step
with PBS for 5 min. The tissue was counterstained with DAPI (4′,6-Diamidin-2-phenylindol).
Frozen brain sections were cut at 14 µm thickness. After cryosections were thawed for 20 min in a
hydrated staining chamber, sections were fixed in 4% paraformaldehyde (PFA)/4% sucrose/PBS for
20 min and washed three times in PBS for 5 min each. Subsequently, sections were treated with 1× PBS
with 0.2% Triton X-100 for 20 min at RT and 1× PBS with 0.05% Triton X-100 for 10 min at RT. To avoid
unspecific antibody binding blocking was performed with blocking solution (BS) (10% FBS in 1× PBS)
for 1 h at RT. Afterwards, the tissue was incubated with primary antibody diluted in BS overnight at
4 ◦C in a humid chamber. The following day after washing with 1× PBS with 0.05% Triton X-100 for
10 min, the tissue was incubated with secondary antibody coupled to alexa488 or alexa568, diluted in
BS, for 2 h at 37 ◦C in a dark humid chamber, followed by a 3× wash steps with 1× PBS with 0.05%
Triton X-100 for 5 min each and a 5 min wash step with 1× PBS. The tissue was counterstained with
DAPI (4′,6-Diamidin-2-phenylindol) for 5 min at RT, washed with aqua bidest before being mounted
with Vecta Mount. Fluorescence images were obtained using an inverted confocal microscope (Zeiss
LSM710, Göttingen, Germany) and an ImageXpress Micro Spinning Disc Confocal High-Content
Imaging System (Molecular Devices, San Jose, CA, USA), and analyses of signal intensities were
performed with ImageJ 1.48r.
4.5. Histology
Paraffin-embedded sections from intestine were obtained of small intestine from adult mice
(10 weeks of age). From each intestine, 4 cm were fixed in 4% buffered formalin. Per sample, three
small parts were embedded in paraffin wax longitudinally (for cross sections) and horizontally (for
longitudinal sections). For morphological analyses, small intestinal sections were cut at 2µm and stained
with Haematoxylin/Eosin (HE) or the periodic acid–Schiff (PAS)-reaction. Immunohistochemistry
staining of 4.5 to 5 µm sections was performed using the Benchmark XT Autostainer (Ventana Medical
systems, Tucson, USA). All required reagents were purchased from Ventana. Dilution of primary
antibodies was done according to the respective manufacturer’s recommendations. For detection of
primary antibody the OptiView DAB IHC Detection Kit or the ultra universal Alkaline Phosphatase Red
Kit was used. Additionally, sections were washed in water, lightly counterstained with Haematoxylin,
dehydrated, and mounted. Images were obtained using the Mirax Desk scanner and the MIRAX
Viewer 1.12.22.0 software (Zeiss, Göttingen, Germany).
4.6. qRT-PCR
Total RNA was isolated with the RNeasy Mini Kit according to the manufacturer’s protocol. All of
the optional purification steps were performed and RNA eluted with sterile RNAse-free water.
cDNA synthesis of pooled RNAs was performed with the iScriptTM cDNA Synthesis Kit (Bio-Rad)
according to the manufacturer’s protocol in a total reaction volume of 20 µL and a maximum of 1 µg
RNA/reaction. Quantitative real-time-PCR was performed using the SSoAdvanced Universal SYBR®
Green Supermix (Bio-Rad) and customized PrimePCR plates in 96 well format with immobilized
primers (Bio-Rad) according to the manufacturer’s protocol with a final reaction volume of 20 µL and
2 ng cDNA/well. Resulting data were analyzed using the hydroxymethylbilane synthase (HMBS)
or Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene as an internal standard to normalize
transcript levels. Cycle threshold (ct) values were calculated by the CFX Manager (Bio-Rad, version
3.1, Hercules, CA, USA).
Alternatively, first strand synthesis and quantitative real-time-PCR amplification were performed
in a one-step, single-tube format using the QuantiFastTM SYBR_Green RT-PCR kit from Qiagen
according to the manufacturer’s protocol in a total volume of 20 µL. Thermal cycling and fluorescent
detection were performed using the Rotor-Gene Q real-time PCR machine (model 2-Plex HRM)
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(Qiagen, Hilden, Germany). The SYBR Green I reporter dye signal was measured. Resulting data were
analyzed using the HMBS gene as an internal standard to normalize transcript levels. Cycle threshold
(ct) values were calculated by the Rotor-Gene Q Software (Qiagen, version 2.0.2, Hilden, Germany).
All quantitative real-time PCR reactions were run in technical triplicates and mean ct-values for each
reaction were taken into account for calculations.
4.7. Protein Biochemistry
To obtain homogenate from GI tissue, small intestinal epithelium was isolated from mesenchyme
following a protocol after Nik and Carlsson [28]. In brief, small intestine was cut into 4–5 cm long
pieces. Gut mucus was removed by gently squeezing it out of the intestine with the blunt point of
tweezers. Each piece was inverted by inserting a rod, securing the intestine at one end with a suture
and pulling the rod back. The rod with the inverted piece was inserted into a pipet tip (1000 µL) and
one end of the intestine pulled onto the tip. After careful removal of the rod, the second end of the
intestinal piece is pinched off with a suture. The inverted intestine with the attached pipet tip was
submerged in cell recovery solution and repeatedly inflated and reflated with air over the course of at
least 30 min per piece. During this time the epithelium is separated from the other intestinal layers.
For lysis, RIPA buffer + PI (Complete EDTA-free Protease Inhibitor Cocktail tablets; Roche, Mannheim,
Germany) is applied to the collected mouse tissue. To disrupt the epithelium a sonicator was used
(4 pulses, lasting 1 s each). Afterwards the lysate was incubated for 2 h at 4 ◦C on a rotator followed by
centrifugation for 20 min at 4 ◦C at 11,700 rpm. Protein concentration was determined by Bradford
protein assay.
To obtain homogenate from liver tissue, tissue was immersed in Hepes Sucrose buffer (10 mM
Hepes, 0.32 M Sucrose) and disrupted using a sonicator (fisherbrand sonic dismembranator 120,
Fisher scientific, Hampton, NH, USA). Proteins were separated by SDS-PAGE and blotted onto
nitrocellulose membranes (GE Healthcare). Immunoreactivity was visualized using horseradish
peroxidase (HRP)-conjugated secondary antibodies and the SuperSignal detection system (Pierce,
Thermo Fisher, Waltham, MA, USA).
4.8. Statistic
Statistical analysis was performed using Graph Pad Prism 5 (La Jolla, CA, USA), and tested
for significance using t tests. All values were normally distributed. In experiments using pooled
samples or three replicates, normal distribution was not tested but assumed as the most likely scenario.
Statistical tests were two tailed with a significance level of α ≤ 0.05. Significances are stated with
p values <0.05 *; <0.01 **; <0.001 ***.
qRT PCR quantification—Relative quantification is based on internal reference genes to determine
virtual mRNA levels of target genes. Cycle threshold (ct) values were calculated by the Rotor-Gene
Q Software (version 2.0.2, Qiagen, Hilden, Germany). Ct values were transformed into virtual
mRNA levels according to the formula: Virtual mRNA level = 10 * ((ct(target) − ct(standart))/slope of
standard curve).
Western blot quantification—Evaluation of bands from Western blots (WBs) was performed using
ImageJ. Three independent experiments were performed and blots imaged using a UVITEC Alliance
Q9 Advanced system (Cleaver scientific, Rugby, UK). The individual bands were selected and the
integrated density was measured. All WB bands were normalized to β-Actin and the ratios averaged
and tested for significance.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/9/2134/
s1.
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